Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Capital Employed (2019 - 2025)

BioNexus Gene Lab's Return on Capital Employed history spans 7 years, with the latest figure at 0.37% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.37% for Q4 2025, down 19.0% from a year ago — trailing twelve months through Dec 2025 was 0.37% (down 19.0% YoY), and the annual figure for FY2025 was 0.32%, down 14.0%.
  • Return on Capital Employed for Q4 2025 was 0.37% at BioNexus Gene Lab, down from 0.3% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.14% in Q4 2021 to a low of 0.39% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 0.09% (2023), against an average of 0.11%.
  • The sharpest move saw Return on Capital Employed plummeted -106bps in 2021, then increased 28bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.14% in 2021, then crashed by -132bps to 0.05% in 2022, then tumbled by -469bps to 0.26% in 2023, then soared by 32bps to 0.18% in 2024, then crashed by -109bps to 0.37% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.37%, 0.3%, and 0.39% for Q4 2025, Q3 2025, and Q2 2025 respectively.